title: Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus.
abstract: OBJECTIVE
  To study the value of surgical treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).
  
  
  METHODS
  From January 1997 to December 2001, 63 cases of HCC with portal vein tumor thrombus underwent liver resection combined with PVTT removal (group 1). Between December 2001 and December 2003, 20 patients received adjuvant portal vein chemotherapy (PVC) after the surgical procedures mentioned above (group 2). Treatment outcome and the surgical features in these two groups were studied.
  
  
  RESULTS
  The median overall survival in group 2 was significantly longer than that in group 1 (10.9 months vs. 7.8 months, p < 0.05). There were significant differences between the survival of the two groups (log-rank, p < 0.05). In group 1 the 1-, 3-, and 5-year survival rates were 18.0%, 14.8% and 1.6%, respectively. In group 2 the 1-year survival rate was 30%.
  
  
  CONCLUSIONS
  Liver resection combined with PVTT removal and the postoperative PVC is beneficial to the survival of HCC patients with PVTT. Postoperative PVC might enhance the effect of these surgical approaches.
authors.affiliation: Department of Hepatobiliary Surgery, First Affiliated Hospital of Sun Yat-Sen University, 58 Zhongshan Road 2, Guangzhou 510080, China. pengbaogang@tom.com
authors.forename: Baogang
authors.initials: B
authors.lastname: Peng
authors.forename: Lijian
authors.initials: L
authors.lastname: Liang
authors.forename: Qiang
authors.initials: Q
authors.lastname: He
authors.forename: Fan
authors.initials: F
authors.lastname: Zhou
authors.forename: Shimin
authors.initials: S
authors.lastname: Luo
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000008:administration & dosage; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D011169:Portal Vein / Q000187:drug effects / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D016019:Survival Analysis; D017131:Thrombectomy; D020246:Venous Thrombosis / Q000188:drug therapy / Q000209:etiology* / Q000601:surgery*
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000431:Ethanol; D016685:Mitomycin; D004317:Doxorubicin; D005472:Fluorouracil